Cost effectiveness of golimumab for the treatment of active psoriatic arthritis

Ewen Cummins, Christian Asseburg, Manishi Prasad, Jacqueline Buchanan and Yogesh Punekar ()

The European Journal of Health Economics, 2012, vol. 13, issue 6, 809 pages

Abstract: Once monthly, golimumab is a cost-effective treatment alternative for patients with active PsA. With its patient-focussed attributes, golimumab is likely to offer additional choice in PsA treatment. Copyright Springer-Verlag 2012

Keywords: Cost effectiveness; Psoriatic arthritis; Golimumab; TNF-α inhibitor; I15 (search for similar items in EconPapers)
Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-011-0335-x (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:13:y:2012:i:6:p:801-809

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-011-0335-x

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().